News and Announcements
Sementis Ltd – CEO Interview
- Published November 13, 2014 11:53AM UTC
- Publisher Wholesale Investor
- Categories Executive Interviews
Sementis is a biotech company developing vaccines for peanut allergy and chikungunya (like dengue fever, a mosquito-borne disease spreading throughout the world). There is an early stage pipeline for vaccines for Ebola, Q Fever, Melanoma (skin Cancer) and prostate Cancer.
The vaccines use Sementis’ “SCV” backbone technology. This is a vaccinia virus (which is also a smallpox vaccine) genetically altered to prevent replication in human cells thus ensuring safety and, through further manipulation, able to increase its immune stimulating properties. The genes for antigens from diseases are added to the SCV, which, with vaccination, elicits an immune response to the disease state in the human body.
Sementis’ Non-executive Chairman, Maurice O’Shannassy spent 25 years in the financial services industry in Australia, the United Kingdom and Asia. His most recent role was that of CEO of BlackRock Investment Management in Australia. Prior to that he was the CEO and CIO of the Asian operations of BlackRock’s antecedents, Merrill Lynch Investment Management and Mercury Asset Management.
Please listen to Sementis’ Non-executive Chairman, Mr. Maurice O’Shannassy.
Executive Interviews
How Capital HQ Slashes Capital Raising Time by 80% for Founders
For startup founders, the capital raise process can feel like a relentless, time-consuming marathon, often diverting precious energy from the core business. “I remember finishing a capital raise at one stage and I remember spending about three months on it and for the money was brought in I thought that money could have been generated […]
The Great Convergence: The $19 Trillion Shift Defining the Next Era of Wealth
A quiet but powerful trend is re-architecting global finance: the great convergence of traditional finance and digital assets. With Boston Consulting Group forecasting the tokenized real-world assets market to hit $16 trillion by 2030, this isn’t speculation—it’s a new institutional reality. Discover the infrastructure being built, the power of tokenization, and how mature DeFi strategies are defining the next era of wealth.
Beyond the Grandstand: Why Australian Sport is the New Asset Class for Family Offices
Australian sport is evolving into a compelling, institutional-grade asset class. Driven by a “golden decade” of major events and significant private capital, it offers high-growth, uncorrelated returns, making it an attractive new frontier for savvy family offices.
Backed By Leading Investment Groups and Family Offices
